GlassScriptPhysician profile
Joy U Akuchie
NPI 1932623329
$5,889.97
in general payments reported to CMS, 2019-2025
42 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $919 · 2022: $1,229 · 2023: $1,534 · 2024: $1,102 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,741.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $733.97 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $578.74 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $539.75 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $492.71 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $395.85 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $272.86 | 2021-2025 | |
| Astellas Pharma US INC | $242.52 | 2021-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $218.79 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $218.20 | 2021-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Janssen Pharmaceuticals, INC | $173.83 | 2021-2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $160.76 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $144.18 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.79 | 2021-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $137.92 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.37 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $128.46 | 2021-2024 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $122.64 | 2021 | |
| Dexcom, INC. | $119.09 | 2021-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $103.97 | 2021-2025 | Otezla, Repatha, Evenity |
| Novartis Pharmaceuticals Corporation | $93.46 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $79.23 | 2022-2024 | Gvoke Hypopen |
| Corcept Therapeutics | $73.94 | 2024 | Korlym |
| Mayne Pharma Commercial LLC | $68.29 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $61.40 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $44.70 | 2022-2024 | Contrave |
| Lundbeck LLC | $44.59 | 2025 | Rexulti |
| Amarin Pharma, INC. | $40.50 | 2021 | |
| Sanofi Pasteur INC. | $39.43 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $37.27 | 2025 | Camzyos |
| Axsome Therapeutics, INC. | $29.24 | 2025 | Auvelity |
| Nestle Healthcare Nutrition INC. | $28.52 | 2022 | |
| Organon LLC | $23.50 | 2025 | Nexplanon |
| Agile Therapeutics, INC. | $21.40 | 2024 | Twirla |
| Ibsa Pharma INC. | $18.56 | 2022 | |
| Ardelyx, INC. | $18.44 | 2024 | Ibsrela |
| Medtronic, INC. | $16.49 | 2024 | Venaseal |
| Impel Pharmaceuticals LLC | $16.21 | 2024 | Trudhesa |
| Ultragenyx Pharmaceutical INC. | $16.09 | 2021 | |
| Dynavax Technologies Corporation | $15.88 | 2025 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $15.14 | 2025 | |
| Amneal Pharmaceuticals LLC | $14.83 | 2025 | Unithroid |
| Esperion Therapeutics, INC. | $14.46 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Akuchie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.